QuartrQuartr

CYTK: Launch momentum builds as nHCM filings and European expansion approach

Moins d'1 minute de lecture

Revenue rose 76% QoQ and dispenses exceeded 2,800; new-to-brand share approached 45% after eight months. Upcoming priorities include the nHCM submission by year-end and potential European activity in early 2027.

Based on Cytokinetics, Incorporated [CYTK] Stifel 2026 Healthcare Conference 2026 Audio Transcript — Nov. 10 2026

Clause de non-responsabilité